ERBB2 and breast carcinoma: Characterized by overexpression of the human epidermal growth factor receptor 2 (HER2) gene and its protein, HER2-positive breast cancer accounts for 20–30% of breast cancer cases and requires distinct therapeutic strategies (2, 3).